Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 233443
For the Non-Exclusive License Grants Licensor grants to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under any such issued patent for Licensee to make, have made, use, sell, offer for sale or import Compound(s) and Product(s) in the Territory.
And, Licensor grants a non-sublicenseable, non-exclusive license to use Licensor 102,677 for the purpose of developing an assay relating to Licensor 21,947 that quantifies the level, if any, of Licensor 102,677 present in Licensor 21,947 in vitro or in vivo.
Compound shall mean Licensor 21,947, and/or Licensor 216,303. For avoidance of doubt, Compound does not include Licensor 102,677.
Licensor 21,947 shall mean the compound having a chemical name (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3. l .0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.
Licensor 102,677 shall mean the compound having a chemical name (-)-l-(3,4-dichlorophenyl)-3-azabicyclo[3. I.0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.
Licensor 216,303 shall mean the compound having a chemical name (Â±)-l -(3,4-dichlorophenyl)-3-azabicyclo[3. I.0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
IPSCIO Record ID: 249736
Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.